Drug Profile
Research programme: sigma1 inhibitors - Context Therapeutics
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Context Therapeutics
- Class Antidementias; Neuroprotectants
- Mechanism of Action Sigma-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Neurodegenerative disorders
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 28 Dec 2021 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA
- 28 Dec 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in USA